Fred Hassan was named Chair of the Board of Recursion Pharmaceuticals, Inc. As of November 6, 2026, Recursion Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 30, 2026 to November 2, 2026, naming 2 appointments (Form 8-K, November 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Recursion Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Recursion Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-30 to 2026-11-02. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Recursion Pharmaceuticals, Inc. files it.
Also on the record for Recursion Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 6.6% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.09% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.97% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.5% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.5% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.2% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by BAILLIE GIFFORD & CO | 4.6% of the class | 5%+ stakes | Source |
| February 3, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 7.25% of the class | 5%+ stakes | Source |
| December 23, 2025 | Stake report, Schedule 13D/A, by Mubadala Investment Co PJSC | 1.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Recursion Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Recursion Pharmaceuticals, Inc. and the records around it.
Recursion Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Mubadala Investment Co PJSC also filed stake reports on 5 other companies: Evotec SE (Oct 2026), GLOBALFOUNDRIES Inc. (Aug 2026), Blue Owl Technology Finance Corp. (Feb 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Tempus AI, Inc. (Nov 2026), 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026)
- BAILLIE GIFFORD & CO also filed stake reports on 39 other companies: QXO, Inc. (Oct 2026), Reddit, Inc. (Oct 2026), Samsara Inc. (Oct 2026)
Watch Recursion Pharmaceuticals, Inc.
Get an email when Recursion Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Recursion Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Recursion Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Recursion Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-02 | In | Chair of the Board | 8-K, 2026-11-02 | ||
| 2026-11-02 | In | 8-K, 2026-11-02 | |||
| 2026-04-30 | Reported | not named in the filing | 8-K, 2026-04-30 |
Who leads Recursion Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chair of the Board: Fred Hassan, appointed (filed 2026-11-02).
New leaders reset buying decisions — get the Full Report on Recursion Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chair of the Board at Recursion Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chair of the Board at Recursion Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Fred Hassan, Chair of the Board
On October 31, 2026, the Board of Directors (the "Board") of the Company, upon the recommendation from its Nominating and Corporate Governance Committee (the "Nominating Committee"), increased the number of members of the Board from 9 to 10 and appointed Fred Hassan as Chair of the Board, effective immediately.
Appointed: Fred Hassan
The Board appointed Mr. Hassan as a Class II Director of the Board, with his initial term to extend until the 2029 Annual Meeting of Stockholders.
- Mr. Hassan has not yet been appointed to any committee of the Board.
Reported
On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the "Board") of Recursion Pharmaceuticals, Inc. (the "Company") and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting").
- Dr. Gibson's decision to not stand for re-election did not result from any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- Dr. Gibson will continue in his role as Chair of the Board and on the committees to which he was appointed until the expiration of his current term at the 2026 Annual Meeting.
Tools for this story
Each opens in a new tab, filled in for Recursion Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.